It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs. It was pretty obvious four … Continue Reading Taking a Look at Trends in Biotherapeutics
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Onpattro (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is the first and only RNA interference (RNAi) therapeutic … Continue Reading Alnylam Receives FDA Approval for First-Ever RNA Interference Therapeutic
Earlier this year, BIO and TEConomy Partners released their 2018 “Investment, Innovation and Job Creation in a Growing U.S. Bioscience Industry” report. It was the eighth biennial report, and focused on the economic progress and the footprint … Continue Reading A Roundup of Biopharma Companies that Announced Hiring Trends So Far this Year
It’s no secret there’s money in the pharmaceutical industry. While chief executive officers and c-suite leaders are often noted for receiving large paychecks, some companies also offer lucrative compensation to employees. This … Continue Reading Pharma and Biotech Companies Provide Top Salaries: Survey
Now that July is over, the U.S. Food and Drug Administration (FDA) appears to be back in full swing with an ample docket of drug decisions to make. There are four therapeutics with … Continue Reading FDA Action Alert: DURECT, Vertex, Alnylam, and Regeneron
In an era of unprecedented drug approvals for rare diseases, two late-stage drugs are upping the ante with their promise to cure disease rather than treat symptoms. First to market … Continue Reading Orphan drugs leveraging new tech promise to cure disease
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a Positive Opinion recommending marketing authorization … Continue Reading Alnylam Receives Positive CHMP Opinion for ONPATTRO™ (patisiran) for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy
Looking ahead to 2018, the most promising products in pharma’s pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with … Continue Reading The 2018 pipeline report: Aspiring assets to keep an eye on
You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA? In this review, we paint an overview of what’s up in a young field that … Continue Reading RNA as a Therapy: Reviewing the Future Generation of Therapeutics
Experts say hemophilia treatment is at a ‘precipice of a therapeutic revolution.’ From antibodies to gene therapy, here are some of the most innovative technologies in the field that might … Continue Reading How is Biotech Innovating to Treat Hemophilia? Let’s Review
